Temozolomide alkylating agent

Temozolomide -alkylating agent -bone marrow suppression-delayed -nausea and vomiting—mild to moderate -constipation -rash -headache -elevated transaminases... 

Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000 5 144-151. 

Liposomal doxorubicin also received initial approval on the basis of response rafe in patients with refractory cancer followed up with a randomized trial of the agent vs. topotecan. The alkylating agent temozolomide was approved in a Phase 11 trial for treatment of patients with anaplastic astrocytoma. Of note is that, although not yet filed for full approval, temozolomide has been recently added on to radiation therapy (e.g., a major trial of radiation therapy with or without temozolomide) for patients with glioblastoma multiforme. The result of this trial showed a major improvement in survival for patients treated with the radiation plus temozolomide vs. those treated with radiation therapy alone (median survival 15 vs. 12 months, p < 0.0001 and 1 year survival 26 vs. 8%, p < 0.0001).25... 

Temozolomide is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma. Apart from myelosuppression the most common adverse effects are nausea and vomiting. 

Monofunctional alkylating agents (dacarbazine and temozolomide) (SEDA-32, 827)... 

---